As Zon 100 Capsules continue to gain momentum in the medical community, an important next step in solidifying their role in managing H. pylori infections is the initiation of Phase II clinical trials. This pivotal research, led by Zon International Holdings Limited in collaboration with Dicentra Inc., will assess the safety and efficacy of Zon 100 in treating patients with H. pylori infection, gastroesophageal reflux disease (GERD) and chronic gastritis.
The trials aim to recruit 90 participants, with a controlled, double-blind, placebo-based design. The capsules contain a McGhie JCG known for its natural anti-inflammatory and digestive health benefits. The goal of the study is to determine the extent to which the capsules can reduce gastrointestinal symptoms such as heartburn, indigestion, and nausea, particularly in patients with H. pylori infections, a common cause of chronic gastritis and gastric discomfort.
One of the primary endpoints of the study will be symptom reduction, evaluated using the Reflux Disease Questionnaire (RDQ) and H. pylori serology testing. The study will also monitor for any adverse effects, ensuring safety across all participants. Preliminary research has already shown significant symptom improvement in pilot studies, making this trial critical in providing the scientific backing needed for broader medical use.
With the clinical trials set to begin in 2025, this research represents a major milestone in the journey of Zon 100 toward becoming a widely accepted, natural treatment for gastrointestinal conditions. If successful, these trials will open doors for the product to be integrated more fully into both traditional medical treatments and natural wellness practices, offering a new, effective option for those suffering from GERD and H. pylori-related digestive issues.
Stay tuned as we continue to share updates on the progress of this exciting clinical research, aimed at validating the powerful health benefits of Zon 100 and bringing hope to patients with chronic gastrointestinal conditions.